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Abstract The homeobox gene Cdx1 is a regulator of intestinal
epithelial cell proliferation and differentiation. Using a transfec-
tion approach, we showed here that the oncogenic activation of
the L-catenin pathway stimulates the endogenous expression of
the Cdx1 mRNA as well as the activity of the Cdx1 promoter in
cancer cells of the human colon. Reciprocally, the paralogue
homeobox gene Cdx2 exerts an inhibitory effect on the basal and
on the L-catenin-stimulated activity of the Cdx1 promoter. The
inhibitory effect of CDX2 requires the intact homeodomain. It is
not dependent on canonical CDX binding sites in the Cdx1
promoter nor on the cis-elements specifically targeted by the
L-catenin/Tcf complex. We conclude that the oncogenically
activated L-catenin and CDX2 have opposite and independent
effects on the Cdx1 homeobox gene. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The mammalian homologues of the Drosophila caudal ho-
meobox gene, Cdx1 and Cdx2, are expressed in many organs
during gastrulation, and they become restricted to the intesti-
nal epithelium during foetal and adult life (for a review, see
[1]). In the gut, Cdx1 is expressed in the crypts where epithe-
lial cells are proliferating, whereas Cdx2 is mainly expressed in
the villi lined by di¡erentiated cells [2]. Consistent with their
distribution along the crypt^villus axis, Cdx1 stimulates cell
proliferation while Cdx2 reduces proliferation, and both genes
promote cell di¡erentiation [3^6]. Thus, these homeobox
genes participate in the control of intestinal homeostasis by
regulating the equilibrium between proliferation and di¡eren-
tiation during the constant renewal of the gut epithelium.
Alteration of cell proliferation/di¡erentiation is thought to
be a major event in the initiation and progression of cancer.
Colorectal cancer is a multistep process linked to the inacti-
vation or loss of expression of tumour suppressor genes and
to the constitutive activation or overexpression of proto-on-
cogenes. Activation of the L-catenin/Tcf pathway, through the
loss of function of the APC tumour suppressor that antago-
nises L-catenin signalling or through the oncogenic activation
of L-catenin itself, represents an early and frequent event in
colorectal cancers [7,8]. Besides, several studies have reported
that colon tumourigenesis also shows modi¢cation in the ex-
pression of Cdx1 and Cdx2. Indeed, Cdx2 decreases in rela-
tion with the tumour grade [9], and a decline of Cdx1 also
occurs in the majority of colon carcinomas [10^12]. However,
we found that Cdx1 is upregulated in more than one third of
the polyps, an early stage during tumour progression (unpub-
lished results). Moreover, ectopic expression of Cdx1 occurs
in adenomas that develop in digestive organs outside the gut,
like the oesophagus, the stomach and the liver [12,13]. In
addition, Cdx1 has a cell transformation capacity assessed
by anchorage-independent growth and tumour development
of Cdx1-expressing cells [14] and it is stimulated by oncogenic
ras [15]. Together, these ¢ndings suggest that Cdx1 has a pro-
oncogenic potential. On the contrary, the decline of Cdx2 in
colorectal cancers [9], along with the fact that this gene inhib-
its cell growth [3^5] and is downregulated by oncogenic ras
[15], led to attribute a tumour suppressor function to Cdx2.
Little is known about the molecular mechanism(s) that reg-
ulate Cdx1. We have previously reported that this homeobox
gene is a target of Wnt/L-catenin/Tcf signalling in embryonic
stem cells as well as during foetal endoderm development [16].
However, it is not known whether the oncogenic activation of
this pathway in colorectal cancer cells also stimulates Cdx1.
Reciprocally, forced expression of CDX2 has been shown to
reduce the level of Cdx1 mRNA in colon cancer cells, raising
the possibility that Cdx2 exerts an inhibitory e¡ect on Cdx1
[4]. The aim of this study was to investigate whether Cdx1 is
targeted by the oncogenic activation of the L-catenin pathway
in colon cancer cells, and whether there is a relation between
L-catenin and CDX2.
2. Materials and methods
2.1. Cell culture and transfection
The human colon adenocarcinoma cell lines Caco2TC7 and HT29,
and the embryonic kidney cells HEK293 were cultured in DMEM
with 20% (Caco2TC7) and 10% (HT29, HEK293) foetal calf serum.
The ¢broblastic cell line RC9 was raised in our laboratory from the
intestinal mesenchyme of neonatal rats and maintained in culture in
DMEM with 10% foetal calf serum. For transfections, cells were in-
cubated 3 h with 3 Wl Exgen500 (Euromedex) per 1 Wg DNA, and the
transfection medium was then replaced with fresh culture medium.
Transfected cells were subsequently incubated at 37‡C for 24 h before
analysis.
2.2. Plasmids
The reporter luciferase plasmids pvPS-Luc and pvAN-Luc contain-
ing 1.5 and 0.7 kb of the murine Cdx1 promoter, the plasmid pvPS-
TBE34m-Luc in which the two proximal Tcf-binding elements (TBEs)
of the Cdx1 promoter were mutated, and the expression plasmid
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pCdx2S encoding the murine CDX2 homeoprotein have been de-
scribed [4,15,16]. Variant forms were derived from pCdx2S using
site-directed mutagenesis (Promega, details are available upon re-
quest): pHA-Cdx2 encodes an HA-tagged version of CDX2; in
pHA-Cdx2-232, the codon encoding Trp232 was changed into a
stop codon; pHA-Cdx2-v1 has an internal 33-bp deletion resulting
in a form of HA-CDX2 lacking Ala217 to Val229. For this study, we
also used pS33A-Lcatenin encoding the oncogenic form of L-catenin
[17], and pcDNA3-TCF4E-myc and pcDNA3-vNTCF4E-myc encod-
ing, respectively, myc-tagged Tcf4 and the N-truncated dominant neg-
ative form of Tcf4 [18]. The reporter plasmid pSI-Luc containing the
fragment 3370/+30 of the human sucrase^isomaltase promoter in-
serted in pGl3-Basic (Promega) has been kindly provided by Dr M.
Rousset (Inserm U.405, Paris, France). The plasmid pMACS-Kk was
from the MACSelect kit (Miltenyi Biotec). pRL-TK (Promega) was
used to standardise cell transfections, and pBluescript (Stratagene)
was used to correct the amount of DNA during transfections.
2.3. RNA analysis
Caco2TC7, HT29 or RC9 cells (2U106) were transfected with 5 Wg
pS33A-Lcatenin, 3 Wg pcDNA3-TCF4E-myc and 2 Wg pMACS-Kk.
Controls were transfected with 8 Wg pBluescript and 2 Wg pMACS-Kk.
After 24 h, cells were trypsinised, labelled with microbeads coated
with anti-H2Kk antibody, and loaded on a column for magnetic sep-
aration according to the protocol described in the MACSelect kit
(Miltenyi Biotec). RNA was extracted from the immunoselected cells
using Tri-Reagent (Euromedex) and analysed by semi-quantitative
RT-PCR under standard conditions previously established to monitor
the Cdx1 and GAPDH transcripts [4,15]. The PCR products were
electrophoresed on 3% agarose gels and analysed using an Imaging
Densitometer (GelDoc 1000, Bio-Rad). The identity of the PCR prod-
ucts was con¢rmed by direct sequencing.
2.4. Luciferase measurement
Caco2TC7, HT29 or HEK293 cells (1.5U105) were transfected with
1 Wg of luciferase reporter plasmid and the appropriate expression
plasmid(s) at 0.5 Wg, unless otherwise stated. They were cotransfected
with 0.02 Wg pRL-TK (Promega) for normalisation. After 24 h, cells
were harvested for luciferase measurements using the Dual Luciferase
Assay (Promega). At least three independent experiments were per-
formed in triplicate for each condition of transfection.
2.5. Western blotting
HEK293 cells (2U106) were transfected with 5 Wg pBluescript or
pHA-Cdx2. After 24 h, cells were washed in PBS, centrifuged at
2500Ug and resuspended in two pellet volumes of lysis bu¡er com-
posed of 200 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.2 mM EDTA,
25% glycerol, 0.5 mM DTT and protease inhibitors (Sigma). NaCl
was added to a ¢nal concentration of 420 mM, and cells were lysed by
two rounds of thaw/freeze at 380‡C. Cell extracts were centrifuged at
12 000Ug and the supernatant was stored at 380‡C [19]. The presence
of CDX2 in the extracts (6 Wg) was analysed by standard SDS^PAGE
(12% polyacrylamide) and Western blotting using anti-HA monoclo-
nal antibody (Eurogentec, dilution 1:1000). The mouse monoclonal
was revealed using peroxidase-coupled anti-mouse antibody (Amer-
sham, dilution 1:4000) and the ECL detection kit (Amersham).
2.6. Immunocytology
HT29 cells (4U104) were transfected with 0.25 Wg of pHA-Cdx2,
pHA-Cdx2-232 or pHA-Cdx2-v1. After 24 h, cells were ¢xed for 20
min in 4% paraformaldehyde. They were incubated in PBS containing
0.25% Triton X100 and anti-HA antibody (Santa Cruz Biotechnology,
dilution 1:200) and then with anti-rabbit antibody coupled to Alexa-
568 (Molecular Probes, dilution 1:1200) in PBS. Nuclei were stained
with Hoechst-33258 (10 Wg/ml, Sigma). Fluorescent staining was vi-
sualised using an Axiophot microscope (Zeiss).
3. Results and discussion
We have reported that the Cdx1 homeobox gene is a target
of the Wnt/L-catenin/Tcf pathway during the normal process
of development in mammals [16]. Since the alteration of this
pathway is a very frequent and early event during colorectal
tumourigenesis, we have investigated if Cdx1 is also targeted
by the oncogenic activation of this pathway in human colon
cancer cells. To this end, two human colon adenocarcinoma
cell lines, Caco2TC7 and HT29, were transfected with the
plasmids pS33A-Lcatenin and pcDNA3-TCF4E-myc that en-
code the oncogenic form of L-catenin and Tcf4, while controls
were transfected with pBluescript. Cells were simultaneously
cotransfected with a limited amount of pMACS-Kk, which
encodes the membrane-anchored H2Kk, to select the success-
fully transfected cells, as they expressed H2Kk at their surface.
As shown in Fig. 1A, the level of Cdx1 mRNA was low in
control Caco2TC7 and HT29 cells, and it increased in both
cell lines transfected with the plasmids encoding the oncogenic
form of L-catenin and Tcf4. Unlike the epithelial cells, no
Cdx1 mRNA was detected in the intestinal mesenchymal cells
RC9, either control or transfected to overexpress the onco-
genic L-catenin and Tcf4. Caco2TC7 or HT29 cells were then
transfected with pS33A-Lcatenin and pcDNA3-TCF4E-myc,
and with the luciferase reporter plasmid pvPS-Luc or
pvAN-Luc containing, respectively, 1.5 or 0.7 kb of the
Cdx1 promoter (Fig. 1B). The activity of both reporters was
stimulated by 2.5-fold as compared to controls (Fig. 1B). This
stimulatory e¡ect was abolished by replacing pcDNA3-
TCF4E-myc with pcDNA3-vNTCF4E-myc encoding a dom-
inant negative form of Tcf4 unable to interact with L-catenin
(not shown). It was also prevented when the two TBEs of the
Cdx1 promoter, previously identi¢ed as the targets of L-cat-
enin signalling during development [16], were destroyed by
point mutagenesis in pvPS-TBE34m-Luc (Fig. 1B). Finally,
when intestinal mesenchymal RC9 cells, instead of the epithe-
lial cell lines, were transfected with pvPS-Luc, luiciferase ac-
tivity was not above the background, and it was not stimu-
lated by cotransfection with pS33A-Lcatenin and pcDNA3-
TCF4E-myc (not shown). Taken together, these data demon-
strate that the oncogenic activation of L-catenin stimulates the
endogenous expression of the Cdx1 mRNA and the transcrip-
Fig. 1. Stimulation of Cdx1 expression by oncogenic L-catenin in
colon cancer cells. A: Human colon cancer cells Caco2TC7 and
HT29, or mesenchymal intestinal cells RC9 were transfected with
pBluescript (lane 1) or with pS33A-Lcatenin and pcDNA3-TCF4E-
myc (lane 2), together with pMACS-Kk. RNA was extracted from
cells immunoselected for the presence of H2Kk at the surface, and
analysed by RT-PCR for Cdx1 and Gapdh mRNA expression.
B: Caco2TC7 and HT29 cells or human embryonic kidney cells
HEK 293 were transfected with 1 Wg of the reporter plasmids pvPS-
Luc (grey), pvAN-Luc (black) or pvPS-TBE34m-Luc (hatched), and
with 0.5 Wg of pS33A-Lcatenin and 0.25 Wg of pcDNA3-TCF4E-
myc. The plasmids pS33A-Lcatenin and pcDNA3-TCF4E-myc were
replaced by pBluescript in the controls (open). Cells were cotrans-
fected with 0.02 Wg pRL-TK for normalisation. Luciferase activity
driven by the promoter was related to renilla luciferase and ex-
pressed as arbitrary units; the value of 100 was attributed to the
controls.
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tional activity of the Cdx1 promoter in colon cancer cells, and
that this e¡ect is cell-type speci¢c. The fold stimulation of the
Cdx1 promoter activity was lower in Caco2TC7 and HT29
cells than in the widely used HEK293 cells (Fig. 1B, see
also [16]), most likely because L-catenin signalling is constitu-
tively activated in both colon cancer cell lines, whereas it is
not in the embryonic kidney cells HEK293.
During the course of these experiments, we have also ana-
lysed the expression of the Cdx1 paralogue in the intestine,
Cdx2, and we failed to demonstrate any obvious change by
oncogenic L-catenin/Tcf4 (not shown). Since Cdx1 and Cdx2
play opposite and complementary roles in the regulation of
intestinal epithelial cell behaviour [3^6], we have investigated
whether the CDX2 homeoprotein has an e¡ect on the basal
and/or on the L-catenin-stimulated activity of the Cdx1 pro-
moter. These experiments were performed using HEK293 cells
because the stimulation of Cdx1 by oncogenic L-catenin is
higher in these cells and because they do not express CDX2
endogenously. Cells were cotransfected with the Cdx1 reporter
plasmid pvPS-Luc or pvAN-Luc and with pCdx2S that en-
codes the murine CDX2 protein. As shown in Fig. 2A, the
transcriptional activity of both Cdx1 promoter segments was
decreased in the presence of CDX2 protein, corroborating our
previous ¢nding that the level of Cdx1 mRNA is reduced in
colon Caco2TC7 cells stably transfected to overexpress CDX2
[4]. The e¡ect of CDX2 was dose dependent, and a signi¢cant
inhibition already occurred at a dose as low as 0.01 Wg
pCdx2S. This prompted us to investigate whether CDX2
can antagonise the stimulatory e¡ect exerted by oncogenic
L-catenin on the Cdx1 promoter. For this purpose, HEK293
cells were cotransfected with pvPS-Luc or pvAN-Luc, with
pS33A-Lcatenin and pcDNA3-TCF4E-myc, and with pCdx2S
at di¡erent doses. Fig. 2B indicates that the four to six fold
stimulation of the Cdx1 promoter activity by oncogenic
L-catenin/Tcf4 was abrogated by the addition of increasing
amounts of pCdx2S. As for the basal activity of the Cdx1
promoter, the L-catenin-stimulated activity was also inhibited
at the lowest concentration of pCdx2S used for this study
(0.01 Wg) (Fig. 2A,B). These results indicate that the CDX2
homeoprotein is a potent inhibitor of the basal and of the
L-catenin-stimulated activity of the Cdx1 promoter.
In an attempt to identify the mechanism of action of the
CDX2 protein, we asked whether the inhibitory role of CDX2
on Cdx1 expression was dependent on Tcf4 bound to the
TBEs of the Cdx1 promoter. Indeed, it has already been
shown that DNA-binding factors of the Tcf family act as
either transcription activators or inhibitors depending on the
cofactors with which they interact (L-catenin or TLE1, respec-
tively). To address this question, we have compared the e¡ect
of CDX2 on the original pvPS-Luc reporter plasmid and on
pvPS-TBE34m-Luc, in which the two TBEs of the Cdx1 pro-
moter were mutated. We showed that pCdx2S exerted the
same inhibitory e¡ect on pvPS-TBE34m-Luc as on pvPS-
Luc either in the absence or in the presence of the plasmids
coding for oncogenic L-catenin and Tcf4 (Fig. 3). This indi-
cated that the inhibition of the Cdx1 promoter by CDX2 is
not mediated by the TBEs needed for the stimulation by
L-catenin/Tcf4. Hence CDX2 and L-catenin exert opposite
e¡ects on Cdx1 using distinct mechanisms.
We next investigated whether an intact CDX2 homeodo-
main was required for its inhibitory e¡ect. For this purpose,
we have constructed the plasmid pHA-Cdx2 that coded for
the HA-tagged version of CDX2, and two derived plasmids
on the basis of mutations reported in homeoproteins other
than CDX2. In pHA-Cdx2-232, the codon corresponding to
Fig. 2. CDX2 inhibits the basal and L-catenin-stimulated activity of
the Cdx1 promoter. A: HEK293 cells were transfected with 1 Wg of
the reporter plasmid pvPS-Luc or pvAN-Luc, without or with in-
creasing amounts of pCdx2S to express the CDX2 protein, and with
pRL-TK to normalise transfections. B: Same as in A except that
cells were also cotransfected with 0.5 Wg of pS33A-Lcatenin and
0.25 Wg of pcDNA3-TCF4E-myc (L-cat + Tcf4) to stimulate the ac-
tivity of the Cdx1 promoter. Luciferase activity driven by the pro-
moter was related to renilla luciferase and expressed as arbitrary
units; the value of 100 was attributed to the controls.
Fig. 3. Mutation of the TBEs of the Cdx1 promoter does not pre-
vent inhibition by CDX2. HEK293 cells were transfected with 1 Wg
of the reporter plasmid pvPS-Luc or pvPS-TBE34m-Luc in which
the two TBEs of the Cdx1 promoter were disrupted, and in the
presence or in the absence of pS33A-Lcatenin and pcDNA3-TCF4E-
myc. The plasmid pCdx2S was added as indicated, and cells were
cotransfected with pRL-TK for normalisation. Luciferase activity
driven by the promoter was related to renilla luciferase and ex-
pressed as arbitrary units; the value of 100 was attributed to the
controls.
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Trp232 within helix-3 of the homeodomain was changed into
a stop codon to delete the 79 amino acids of the C end of
CDX2. The corresponding mutation in the human HoxA13
gene is responsible for the Hand^Foot^Genital syndrome [20].
The second plasmid, pHA-Cdx2-v1, encodes a protein variant
in which 11 amino acids were deleted at the boundary between
helix-2 and helix-3 of the homeodomain (from Ala217 to
Val229). Deletion of the corresponding v1 sequence in the
engrailed homeoprotein prevents nuclear export and intercel-
lular transfer [21,22]. Immuno£uorescence staining with anti-
HA antibody in transfected HT29 cells con¢rmed the nuclear
localisation of HA-CDX2 although a faint staining was also
detected in the cytoplasm; the HA-CDX2-232 protein was
nuclear and also showed a punctuate staining in the cyto-
plasm, while HA-CDX2-v1 exhibited a weak signal only in
the nucleus (Fig. 4A). Western blotting of the transfected cells
con¢rmed that proteins of expected size were produced in the
cells, although HA-CDX2-v1 was present at a relatively low
level (Fig. 4B). The activity of the variant forms of CDX2 was
checked by cotransfection with the sucrase^isomaltase pro-
moter as reporter target (Fig. 4C). HA-CDX2 stimulated
this promoter as did the wild-type protein, but HA-CDX2-
232 and HA-CDX2-v1 were both inactive. When the plasmids
pHA-Cdx2-232 or pHA-Cdx2-v1 were introduced into
HEK293 cells together with pvPS-Luc, pS33A-Lcatenin and
pcDNA3-TCF4E-myc, the Cdx1 promoter was not inhibited,
indicating that an intact homeodomain is required for the
inhibitory e¡ect of CDX2 (Fig. 4D).
The Cdx1 promoter fragment inserted in pvPS-Luc con-
tains two putative binding sites for CDX proteins, T/CATA-
AAT/G [23]. The upstream-most site does not mediate the
inhibitory e¡ect of CDX2 since it is not present in the frag-
ment contained in pvAN, which is inhibited by CDX2 (see
Fig. 2). The second site corresponds to the TATA-box of the
Cdx1 gene. An inhibitory role of CDX2, associated to TATA-
box binding, has already been reported in the case of the
calbindin-D9K gene [24]. To investigate whether CDX2 can
bind the Cdx1 TATA-box, EMSA was performed using nu-
clear extracts of pHA-Cdx2-transfected cells and a labelled
double-stranded oligonucleotide overlapping the Cdx1
TATA-box. No speci¢c band supershifted with anti-CDX2
antibody was detected in these experiments. We also failed
to detect any bandshift using in vitro transcribed/translated
CDX2 (not shown).
In summary, we have demonstrated that the oncogenic ac-
tivation of the L-catenin/Tcf pathway stimulates Cdx1 expres-
sion in adult colorectal cancer cells. This is in line with the
stimulation of Cdx1 by Wnt during foetal development [16].
In addition we showed that the CDX2 homeoprotein is a
potent inhibitor of the basal and L-catenin-stimulated activity
of the Cdx1 promoter. Although the mechanism by which
CDX2 downregulates Cdx1 has not been elucidated, one
can conclude that the opposite e¡ects of CDX2 and L-catenin
are independent. Although we were not able to demonstrate
any interaction between CDX2 and the Cdx1 TATA-box in
vitro, we cannot rule out that this occurs in vivo or that
CDX2 interacts with unconventional binding sites to be iden-
ti¢ed in the Cdx1 promoter. Alternatively, the e¡ect of CDX2
could be indirect. Indeed, a number of homeoproteins have
been shown to exert a transcriptional repression e¡ect in a
DNA-binding-independent fashion in Drosophila [25^27].
Moreover, the activity of p300/CBP acetyltransferases, which
bind to and potentiate the function of L-catenin [28,29], can
be inhibited by Hox proteins via a non-DNA-dependent
mechanism involving protein^protein interactions through
the homeodomain helix-3 [30]. The opposite e¡ects of L-cat-
enin and CDX2 on Cdx1 gene expression correlate well with
the oncogenic role of L-catenin signalling and with the tumour
suppressor function attributed to CDX2. We propose that the
balance between activated L-catenin and CDX2 may partici-
pate in the control of Cdx1 expression, which in turn contrib-
utes to the regulation of cell growth and resistance to apopto-
sis [6,14].
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